Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : À¯Çüº°, ÀÓ»ó ½Ç½Àº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Psychiatric Digital Biomarkers Market Size, Share & Trends Analysis Report By Type, By Clinical Practice, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1631470
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 12¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 100 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå µ¿Çâ
¼¼°è Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2024³â 6¾ï 3,129¸¸ ´Þ·¯·Î 2025-2030³â±îÁö ¿¬Æò±Õ 24.35%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤½ÅÁúȯÀÇ À¯º´·ü Áõ°¡, µðÁöÅÐ Çコ ±â¼úÀÇ ¹ßÀü, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. 2024³â 4¿ù, Sensors´Â µðÁöÅРǥÇöÇü ºÐ·ù°¡ ½Å°æÁúȯ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ¸®ºä¸¦ ¹ßÇ¥Çϸç, ¿ø°ÝÀÇ·á¿Í ¼¾¼ ±â¼úÀ» ÅëÇØ ÀÓ»ó °Ë»ç¸¦ °³¼±Çϰí Á¶±â ¹ß°ß°ú ¸ð´ÏÅ͸µÀ» Áö¿øÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» Á¦½ÃÇß½À´Ï´Ù.
¿ì¿ïÁõ, ºÒ¾ÈÀå¾Ö, ¾ç±Ø¼º Àå¾Ö, Á¶Çöº´°ú °°Àº Á¤½ÅÁúȯÀº Àü ¼¼°è ¼ö¹é¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, 2023³â Mental Health America, IncÀÇ ¹ßÇ¥¿¡ µû¸£¸é 12-17¼¼ û¼Ò³âÀÇ 20.17%°¡ ÁÖ¿ä ¿ì¿ïÁõ ¿¡ÇǼҵ带 °æÇèÇß°í, 15%°¡ ÀÏ»ó »ýȰ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½É°¢ÇÑ Àå¾Ö¸¦ °Þ°í ÀÖ½À´Ï´Ù. ÀÏ»ó»ýȰ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½É°¢ÇÑ Àå¾Ö¸¦ °Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯º´·ü Áõ°¡´Â Á¤½Å°Ç° »óŸ¦ ¸ð´ÏÅ͸µÇÏ°í °ü¸®ÇÒ ¼ö ÀÖ´Â º¸´Ù È¿°úÀûÀÎ µµ±¸ÀÇ Çʿ伺°ú Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ °ü½ÉÀÇ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. 2022³â 7¿ù, Pervasive and Mobile Computing Àú³ÎÀº ¿ì¿ïÁõ ȯÀÚ¿Í ¿ì¿ïÁõ ȯÀÚ¿Í ºñ¿ì¿ïÁõ ȯÀÚ »çÀÌ¿¡ ±âºÐ°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿(¼ö¸é, ½º¸¶Æ®Æù »ç¿ë·® µî)¿¡ À¯ÀǹÌÇÑ Â÷À̰¡ ÀÖ´Ù´Â Á¶»ç °á°ú¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ´Üµ¶À¸·Î ¶Ç´Â ±âºÐ Æò°¡¿Í °áÇÕÇÏ¿© ¿ì¿ïÁõ »óŸ¦ Á¤È®ÇÏ°Ô ¿¹ÃøÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î È®ÀεǾú½À´Ï´Ù.
µðÁöÅÐ Çコ ±â¼úÀÇ ¹ßÀüÀº Á¤½Å°Ç° ºÐ¾ß¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI), ¸Ó½Å·¯´×, µ¥ÀÌÅÍ ºÐ¼®°ú °°Àº ±â¼ú Çõ½ÅÀº °³ÀÎÀÇ Á¤½Å°Ç° »óÅ¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇϴ ÷´Ü µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °³¹ßÇÒ ¼ö ÀÖ°Ô ÇØÁÖ¾úÀ¸¸ç, AI ±â¹Ý ¾Ë°í¸®ÁòÀº ½º¸¶Æ®Æù ¼¾¼ÀÇ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© Á¤½Å°Ç° À§±âÀÇ Ãʱâ ¡Èĸ¦ ³ªÅ¸³»´Â Çൿ ÆÐÅÏÀÇ º¯È¸¦ °¨ÁöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. 2023³â 11¿ù, Frontiers in Psychiatry Àú³Î¿¡ ½Ç¸° ±â»ç´Â ½º¸¶Æ®Æù µ¥ÀÌÅÍ·Î ¿ì¿ïÁõ°ú Ä¡·á ¹ÝÀÀÀ» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÀáÀç·ÂÀ» °Á¶Çϸç, ±âºÐÀå¾Ö ¿¹Ãø°ú °ü¸®¿¡ ÀÖ¾î µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °¡´É¼ºÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ±â±â·Î ½ÇÁ¦ ȯ°æ¿¡¼ ±âºÐÀå¾Ö¸¦ º¸´Ù Á¤È®ÇÏ°Ô ÃßÀûÇÒ ¼ö ÀÖÀ¸¸ç, AIÀÇ ¹ßÀüÀ¸·Î »õ·Î¿î Áø´Ü°ú Ä¡·áÀÇ ±æÀÌ ¿¸®°í ÀÖ´Ù´Â Á¡À» ÁöÀûÇÏ¿´½À´Ï´Ù.
ÀÇ·á Á¦°øÀÚ°¡ ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó Ä¡·á °èȹÀ» ¼¼¿ì·Á°í ³ë·ÂÇÔ¿¡ µû¶ó, Á¤½ÅÀÇÇÐ ºÐ¾ß¿¡¼´Â ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿´Â ȯÀÚÀÇ Áõ»ó°ú Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ °´°üÀûÀÎ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á ¸ÂÃãÇü ÁßÀ縦 °¡´ÉÇÏ°Ô ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. 2022³â 3¿ù, DTU Health TechÀÇ ¿¬±¸ °³¹ßÀÚµéÀº À½¼º ºÐ¼®À» ÅëÇØ °³ÀÎÀÇ ¾ç±Ø¼º Àå¾Ö¸¦ ½Äº°Çϰí ȯÀÚÀÇ ±âºÐ º¯È¸¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» °³¹ßÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/º¸Á¶ÀûÀÎ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ºÐ¼® Åø
- »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : À¯Çüº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå À¯Çü º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, À¯Çüº°, 2018-2030³â
- ¿þ¾î·¯ºí
- ¸ð¹ÙÀÏ ±â¹Ý ¿ëµµ
- ¼¾¼
- ±âŸ
Á¦5Àå Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÀÓ»ó ½Çõº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ÀÓ»ó ½Çõ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÀÓ»ó ½Çõº°, 2018-2030³â
- Áø´Ü Á¤½Å ÀÇ·á µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
- Á¤½Å ÀÇ·á µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
- Á¤½ÅÁúȯ ¿¹Ãø°ú ¿¹Èĸ¦ ¿¹ÃøÇÏ´Â µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
- ±âŸ(¾ÈÀü¼º, ¾à·ÂÇÐ/¹ÝÀÀ, °¨¼ö¼º)
Á¦6Àå Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
- ÀÇ·á ±â¾÷
- ÀÇ·á Á¦°øÀÚ
- ÁöºÒÀÚ
- ±âŸ(ȯÀÚ, °£º´ÀÎ)
Á¦7Àå Á¤½Å°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â°ú 2030³â
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- ½º¿þµ§
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- ±â¾÷/°æÀï ºÐ·ù
- Àü·« ¸ÅÇÎ
- ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2023³â
- ±â¾÷ °³¿ä/»óÀå ±â¾÷
- Koneksa
- Biogen Inc.
- Empatica Inc.
- Vivo Sense
- IXICO plc
- Huma
- Sonde Health, Inc.
- Clario
ksm
¿µ¹® ¸ñÂ÷
Psychiatric Digital Biomarkers Market Trends:
The global psychiatric digital biomarkers market size was valued at USD 631.29 million in 2024 and is projected to grow at a CAGR of 24.35% from 2025 to 2030. Increasing prevalence of mental health disorders, advancements in digital health technologies and growing demand for personalized medicine drive the psychiatric digital biomarkers market. Rising adoption of wearable devices and mobile health apps in mental healthcare contribute to the market growth. In April 2024, Sensors published a review on digital phenotyping's impact on neurological diseases, showing its potential to refine clinical trials and aid in early detection and monitoring through telemedicine and sensor technologies.
The global burden of mental health disorders is on the rise, with conditions such as depression, anxiety, bipolar disorder, and schizophrenia affecting millions of people worldwide. In 2023, Mental Health America, Inc found that 20.17% of youths aged 12-17 had encountered a major depressive episode, with 15% suffering severe impairment affecting daily activities. This increasing prevalence is driving the need for more effective tools to monitor and manage mental health conditions, leading to a growing interest in psychiatric digital biomarkers. In July 2022, Pervasive and Mobile Computing published findings showing significant differences in mood and digital markers (such as sleep and phone usage) between depressed and non-depressed individuals. It also confirmed that depression status could be accurately predicted using these digital biomarkers alone or combined with mood ratings.
Technological advancements in digital health technologies revolutionize the field of mental healthcare. Innovations such as artificial intelligence (AI), machine learning, and data analytics enable the development of sophisticated digital biomarkers that provide valuable insights into an individual's mental health status. AI-powered algorithms analyze data from smartphone sensors to detect changes in behavior patterns that indicate early signs of a mental health crisis. In November 2023, an article in Frontiers in Psychiatry highlighted the potential of digital biomarkers in predicting and managing mood disorders, noting how smartphone data can monitor depression and treatment responses, wearable devices can track mood disorders more accurately in real-world settings, and AI advancements are opening up new diagnostic and therapeutic avenues.
There is a growing demand for personalized medicine in mental healthcare, as healthcare providers seek to tailor treatment plans to individual patients' needs. Psychiatric digital biomarkers play a crucial role in enabling personalized interventions by providing objective data on patients' symptoms and treatment responses. The increasing adoption of wearable devices and mobile health apps further fuels this trend, allowing for continuous monitoring of patients outside traditional clinical settings. In March 2022, DTU Health Tech researchers developed a method using voice analysis to identify bipolar disorder in individuals and monitor mood changes in patients, with personalized models providing the most accurate results.
Global Psychiatric Digital Biomarkers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psychiatric digital biomarkers market report based on type, clinical practice, end-use, and region.
- Type Outlook (Revenue, USD Million, 2018 - 2030)
- Wearable
- Mobile based Applications
- Sensors
- Others
- Clinical Practice Outlook (Revenue, USD Million, 2018 - 2030)
- Diagnostic Psychiatric Digital Biomarkers
- Monitoring Psychiatric Digital Biomarkers
- Predictive and Prognostic Psychiatric Digital Biomarkers
- Other's (Safety, Pharmacodynamics/ Response, Susceptibility)
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Healthcare companies
- Healthcare Providers
- Payers
- Others (Patient, caregivers)
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Type
- 1.2.2. Clinical Practice
- 1.2.3. End Use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Psychiatric Digital Biomarkers Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of mental health disorders,
- 3.2.1.2. Advancements in digital health technologies
- 3.2.1.3. Growing demand for personalized medicine
- 3.2.1.4. Rising adoption of wearable devices and mobile health apps
- 3.2.2. Market restraint analysis
- 3.2.2.1. Regulatory hurdles
- 3.3. Psychiatric Digital Biomarkers Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
Chapter 4. Psychiatric Digital Biomarkers Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Psychiatric Digital Biomarkers Market Type Movement Analysis
- 4.3. Global Psychiatric Digital Biomarkers Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. Wearable
- 4.4.1. Wearable market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Mobile based Applications
- 4.5.1. Mobile based applications market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Sensors
- 4.6.1. Sensors market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Psychiatric Digital Biomarkers Market: Clinical Practice Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Psychiatric Digital Biomarkers Market Clinical Practice Movement Analysis
- 5.3. Global Psychiatric Digital Biomarkers Market Size & Trend Analysis, by Clinical Practice, 2018 to 2030 (USD Million)
- 5.4. Diagnostic Psychiatric Digital Biomarkers
- 5.4.1. Diagnostic psychiatric digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Monitoring Psychiatric Digital Biomarkers
- 5.5.1. Monitoring psychiatric digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Predictive and Prognostic Psychiatric Digital Biomarkers
- 5.6.1. Predictive and prognostic psychiatric digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Other's (Safety, Pharmacodynamics/ Response, Susceptibility)
- 5.7.1. Other's (safety, pharmacodynamics/ response, susceptibility) market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Psychiatric Digital Biomarkers Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Psychiatric Digital Biomarkers Market End Use Movement Analysis
- 6.3. Global Psychiatric Digital Biomarkers Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 6.4. Healthcare Companies
- 6.4.1. Healthcare companies market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Healthcare Providers
- 6.5.1. Healthcare providers market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Payers
- 6.6.1. Payers market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Others (Patient, Caregivers)
- 6.7.1. Others (patient, caregivers) market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Psychiatric Digital Biomarkers Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2023 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework
- 7.4.1.3. Competitive scenario
- 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework
- 7.4.3.3. Competitive scenario
- 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework
- 7.5.1.3. Competitive scenario
- 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework
- 7.5.3.3. Competitive scenario
- 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework
- 7.5.5.3. Competitive scenario
- 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Norway
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework
- 7.5.7.3. Competitive scenario
- 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework
- 7.5.8.3. Competitive scenario
- 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework
- 7.6.2.3. Competitive scenario
- 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework
- 7.6.3.3. Competitive scenario
- 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework
- 7.6.5.3. Competitive scenario
- 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework
- 7.8.1.3. Competitive scenario
- 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework
- 7.8.3.3. Competitive scenario
- 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework
- 7.8.4.3. Competitive scenario
- 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company/Competition Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2023
- 8.4. Company Profiles/Listing
- 8.4.1. Koneksa
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Type benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. Biogen Inc.
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Type benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Empatica Inc.
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Type benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. Vivo Sense
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Type benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. IXICO plc
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Type benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Huma
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Type benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Sonde Health, Inc.
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Type benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Clario
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Type benchmarking
- 8.4.8.4. Strategic initiatives
°ü·ÃÀÚ·á